Specific Technologies

Specific Technologies announces new results and a major new NIAID grant award

Specific Technologies has developed a new paradigm for quantitative determination of antibiotic efficacy with minimal sample preparation and at a low cost. The SpeciFAST system offers phenotypic MIC matching CLSI gold standard results in most cases within 3 hours from positive blood culture.

SourceSpecific Technologies·DateJan 4, 2017

Specific Technologies awarded $2.8 million NIH Commercialization Readiness Program grant

The SpecID system combines detection and identification into a single step, offering faster answers and streamlined workflow for clinical microbiology laboratories. The $2.8M award supports the development of quality and manufacturing systems required for regulatory clearance, bridging the gap between manufacture and clinical trials.

SourceSpecific Technologies·DateJun 13, 2016